Tech Company Financing Transactions
Orbus Therapeutics Funding Round
On 8/21/2015, Orbus Therapeutics raised $32.5 million in Series A funding from H.I.G. Capital, Longitude Capital Management and Adams Street Partners.
Transaction Overview
Company Name
Announced On
8/21/2015
Transaction Type
Venture Equity
Amount
$32,500,000
Round
Series A
Investors
H.I.G. Capital (Lead Investor)
Longitude Capital Management (Lead Investor) (Patrick Enright)
Proceeds Purpose
The funding will enable Orbus Therapeutics to conduct a Phase 3 clinical trial evaluating its promising therapeutic product candidate, eflornithine.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
2479 East Bayshore Rd. 105
Palo Alto, CA 94303
USA
Palo Alto, CA 94303
USA
Phone
Website
Email Address
Not Recorded
Overview
Orbus Therapeutics is dedicated to developing products that treat rare diseases for which there are few, if any, effective therapies.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Robert Myers
Chief Operating Officer
Jason Levin
Browse more venture capital transactions:
Prev: 8/21/2015: Vurb venture capital transaction
Next: 8/24/2015: Arcimoto venture capital transaction
Share this article
Where The Data Comes From
We do our best to document tech company VC transactions. VC investment data records on this site are sourced from a variety of public sources. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs